Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CLTR COULTER PHARMACEUTICAL -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (458)	12/10/1999 2:40:00 PM
From: RCMac	Read Replies (1) \| Respond to of 666

>>Thanks for the EXTENSIVE due diligence; we owe you a beer. Heck, as soon as the BLA is accepted we owe you a keg and the St. Bernard to carry it.<< I was thinking maybe a KEG with something like a team of Clydesdales to pull it. Again thanks, Gordon. --RCM

To: biowa who wrote (458)	12/10/1999 10:19:00 PM
From: Bob L	Read Replies (1) \| Respond to of 666

<I still think the issue of excluding patients from the Zev clinical trials based on the In-dosimetry could be sticky. > In the article linked in reply #413, they say: "All patients were eligible for IDEC-Y2B8 treatment on day 7 based on MIRDOSE3 software (Oak Ridge Associated Universities, Oak Ridge, TN) dosimetry estimates from the IDEC-In2B8 scans and IDEC-In2B8 blood activity. The upper limit of acceptable radiation dose was defined as 20 Gy for normal organs and 3 Gy for bone marrow. One patient was not treated based on site-specific (non-MIRDOSE), image-based, bone marrow dosimetry, although the estimated marrow radiation dose was acceptable on blood-derived and sacral image—derived MIRDOSE3 dosimetry performed by the central dosimetrist (Oak Ridge Institute for Science and Education)." I can't quite figure out what they are saying about why they didn't treat one patient. Can someone dumb it down for me?